Sector News

Bayer CEO Baumann faces revolt from investor Temasek Holdings: report

March 31, 2022
Life sciences

With Bayer on an uptick and CEO Werner Baumann seemingly free from investor pressure, a new push is underway, led by Temasek Holdings of Singapore, for a change in leadership.
A major investment by Temasek Holdings of Singapore helped Bayer pull off a risky $63 billion purchase of Monsanto in 2018. But four years later, Temasek is blaming CEO Werner Baumann for a deal gone bad.

With a shareholder meeting set for April 29, Temasek has informed Bayer chairman Norbert Winkeljohann that it wants a change in leadership, according to a report from Bloomberg News. The investor is requesting a no-confidence vote in Baumann or a vote against ratifying the performance of management.

Another investor, Alatus Capital also has joined the call.

“The actions of Mr. Baumann have led to significant shareholder value destruction at Bayer,” wrote (PDF) Alatus in a release. “Bayer’s share price has declined by 48%, significantly underperforming market indexes and peers.”

Baumann, who took over as CEO of the conglomerate in 2016, has been under fire since the poorly-timed acquisition of Monsanto—just as the American firm was facing a growing mountain of litigation over weedkiller Roundup. The cost of the litigation has forced Bayer to sell certain assets across each of its sectors, including pharma.

In addition to displeasure over the Monsanto deal, some investors, including Alatus in its release, have urged Bayer to follow an industry trend by separating its pharma, crop science and consumer health sectors. But Baumann has resisted that pressure.

The news comes as Baumann, who has a contract through April 2024, had seemed in the clear. He survived a no-confidence vote in 2019 and at two other stockholder meetings where his leadership was questioned. The company’s performance has been on an uptick lately, including in the pharma sector.

After selloffs following the Monsanto deal, Bayer’s pharma revenue had dropped from €25.32 billion in 2018 to €23.71 billion in 2019, and then to €22.56 billion in 2020.

But last year saw a reversal with a 10% increase in sales, propelled largely by a strong performance from Eylea. The macular degeneration treatment generated €2.9 billion, representing a 19% bump from 2020.

The company also has a stable of products that are on the upswing including kidney disease blockbuster to-be Kerendia, X-ray agent Ultravist, blood pressure medicines Adalat and Adempas and birth control offerings such as Mirena and Yasmin.

Temasek has a 4% stake in Bayer. Another of its investors, Alatus Capital, also has reportedly agitated for the departure of Baumann. It’s unclear whether Temasek and Alatus have the backing from other investors to pull off the coup, Bloomberg said.

“An early termination of his contract would only cause chaos,” Janne Werning of Union Investment, which supports Baumann, told Bloomberg.

Marc Tungler of the German Association for the Protection of Securities (DSW) called the Temasek initiative “absurd theater, in terms of content and timing,” in comments to the German daily Handelsblatt.

“Now, in a phase in which Bayer is gaining a foothold again and is in an upward trend, such an attack alone can cause damage,” Tungler said.

By Kevin Dunleavy

Source: fiercepharma.com

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach